Podocalyxin is expressed in normal and leukemic monocytes.

Area of Science:

• Hematology
• Oncology
• Cell Biology

Background:

• Acute myeloid leukemia (AML) is a heterogeneous group of hematologic malignancies.
• Understanding specific cell surface markers can improve AML classification and prognosis.
• Podocalyxin's role in AML, particularly its association with specific subtypes, requires further elucidation.

Purpose of the Study:

• To investigate the expression of podocalyxin in acute myeloid leukemia (AML) blast cells.
• To determine the association of podocalyxin expression with immunophenotype, clinical features, and prognostic markers in AML.
• To explore the potential lineage origins and differentiation capacity of podocalyxin-positive AML cells.

Main Methods:

• Analysis of podocalyxin expression in primary leukemic blast cells from 73 AML patients.
• Immunophenotypic analysis of membrane markers (e.g., CD123, CD135, VLA-4, CXCR4).
• Assessment of co-expression of vascular endothelial growth factor receptors (VEGF-R) and related factors, and evaluation of endothelial differentiation potential.

Main Results:

• Podocalyxin was expressed in a subset of AML patients (moderate in 15, high in 13).
• Podocalyxin expression correlated with a monocytic immunophenotype and poor prognostic markers (high blast count, elevated CD123, CD135, VLA-4, CXCR4).
• Podocalyxin-positive AML cells expressed VEGF receptors and angiopoietin-1, and could differentiate into endothelial cells.

Conclusions:

• Podocalyxin serves as a marker for AML with a monocytic phenotype.
• Podocalyxin-positive AML may arise from common myeloid and endothelial progenitor cells.
• These findings suggest a potential link between the monocytic lineage and podocyte biology.